ClinicalTrials.gg
Active, not recruitingNCT05846230Updated Oct 14, 2026

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

A Phase 2 interventional study of BI 1291583 and Placebo matching BI 1291583 in Bronchiectasis, sponsored by Boehringer Ingelheim. Active, not recruiting at 103 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Updated Oct 14, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
17th of 52
268 · median 78
Started
2023
with 2 others
Phase 2
15 of 65
4 open now
Primary completion
2027-03
later than 8 of 21 live
Registered
44th of 65
by date
Lead sponsor
5 of 65
Boehringer Ingelheim

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 17th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2023, is one of 15 in phase 2, reaches primary completion later than 8 of the 21 other live ones, and was the 44th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term.

Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the AirleafTM or ClairaflyTM study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the AirleafTM or ClairaflyTM study continue to take the same dose.

Participants visit the study site 10 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.

03

Conditions studied

  • Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the treatment period in Phase II trials (1397-0012 or 1397-0013) as planned per protocol.
  • Male or female patients. Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the patient information.
  • Signed and dated written prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion criteria

Exclusion Criteria:

Laboratory and medical examination

  • Moderate or severe liver disease (defined by score B or C hepatic impairment) or (AST) and/or alanine aminotransferase (ALT) >3.0x (ULN) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
  • Estimated (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \<30 mL/min at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
  • An absolute blood \<1,000/mm\^3 (equivalent to \<1,000 cells/μL or \<10\^9 cells/L) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
  • Any findings in the medical examination and/or laboratory value assessed at Visit 1 (or at the last safety assessment in the parent trial, concerning the lab tests, if no more than 6 weeks passed since then), that in the opinion of the investigator may put the patient at risk by participating in the trial.

New concomitant diagnosis and therapy

  • A new diagnosis of

    • Hypogammaglobulinemia
    • Common variable immunodeficiency
    • α1-antitrypsin deficiency being treated augmentation therapy
    • Allergic bronchopulmonary aspergillosis being treated or requiring treatment
    • Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
    • Palmoplantar keratosis; or keratoderma climactericum
    • Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
    • Psoriasis affecting palms and soles; or body surface area for psoriasis ≥10%
    • Reactive arthritis (Reiter's syndrome); keratoderma blennorrhagicum
    • Pityriasis rubra pilaris
    • Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis ≥10%
    • Active extensive verruca vulgaris, as per investigator's discretion
    • Active fungal infection of hand and/or feet not adequately treated and responsive to antifungal therapy, as per investigator's discretion.
  • Any respiratory infection within 4 weeks prior Visit 2, unless recovered in the opinion of the investigator by Visit 2.
  • Any acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2.
  • Positive serological tests for , (also confirmed with ( Hepatitis C Virus ribonucleic acid test (HCV RNA))), or (HIV) infection, or known infection status at Visit 2. (The test results will be available after randomisation. In case the results no longer satisfy the entry criteria, these patients will be discontinued.)
  • Any new evidence of a concomitant disease, such as Papillon-Lefèvre Syndrome (PLS), relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the trial.
  • Received any within 4 weeks prior to Visit 1.
  • Further exclusion criteria apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
268 participants (actual)

Study arms

  • Experimental
    BI 1291583 low dose arm

    Drug: BI 1291583 · Drug: Placebo matching BI 1291583

  • Experimental
    BI 1291583 medium dose arm

    Drug: BI 1291583 · Drug: Placebo matching BI 1291583

  • Experimental
    BI 1291583 high dose arm

    Drug: BI 1291583 · Drug: Placebo matching BI 1291583

Interventions

  • Tablet

    Also known as: Verducatib

  • DrugPlacebo matching BI 1291583

    Tablet

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment-emergent adverse events (TEAEs)

    Time frame: up to 12 months

Secondary outcomes

  1. Time to first pulmonary exacerbation from first drug administration in this trial to the end of the trial

    A pulmonary exacerbation in this trial is defined as having three or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics (oral or intravenous): * Increased cough * Increased sputum volume or change in sputum consistency * Increased sputum purulence * Increased breathlessness and/or decreased exercise tolerance * Fatigue and/or malaise * Hemoptysis

    Time frame: up to 12 months

  2. Rate of pulmonary exacerbations (number of events per person-time) over the course of this trial

    Time frame: up to 12 months

07

Study locations

103 sites

Showing the first 100 of 103 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Badorrek P, Diefenbach C, Kogler H, Eleftheraki A, Seitz F, Hohlfeld JM. Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers. Clin Transl Sci. 2024 Aug;17(8):e13891. doi: 10.1111/cts.13891. PubMed 39175217 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Mar 2027, 42 months after the start.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 6, 2023
StartActual
Sep 8, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Bulgaria, 1 Turkey (Türkiye))
  • Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov-Ruse · Rousse, Bulgaria
  • Sureyyapasa Egitim ve Arastirma Hastanesi · Istanbul, Turkey (Türkiye)
Show 1 removed
  • SHATPPD "Dr. Dimitar Gramatikov" · Rousse, Bulgaria
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Bulgaria, 1 Turkey (Türkiye))
    • Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov-Ruse · Rousse, Bulgaria
    • Sureyyapasa Egitim ve Arastirma Hastanesi · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • SHATPPD "Dr. Dimitar Gramatikov" · Rousse, Bulgaria
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05846230
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Sep 8, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verducatib

Start the discussion